Drugs / AMG 208
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00813384 | Dec 2008 → Feb 2013 | cancer | Amgen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02420587 | Oct 2014 → Oct 2019 | prostate cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813384 ↗ |
| Action | Inhibit | “AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation.” NCT00813384 ↗ |
| Modality | Small molecule | “AMG 208 is a small molecule inhibitor of c-Met” NCT00813384 ↗ |
| Route | Oral | “Patients received AMG 208 orally on days 1 and days 4-28 once daily.” PMID 26155941 ↗ Jul 2015 |
| Target | MET | “AMG 208 is a small molecule inhibitor of c-Met” NCT00813384 ↗ |